Jamie Altman, MD
Dermatology · Media, PANPI 1932139342
Payments from drug & device makers
Across 23 payments — averaging $25.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Galderma Laboratories, L.p.$171
- AbbVie$103
- Johnson & Johnson$55
- Novartis$52
- Botanix SB Inc$44
- Sanofi$30
- plus $123 from 7 others
What the payments were for
- Speaking & faculty fees$15026%
- Food & beverage$42874%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Galderma Laboratories, L.p. | 2 | $171 |
| AbbVie(2 entities) | 5 | $103 |
| Johnson & Johnson | 3 | $55 |
| Novartis | 3 | $52 |
| Botanix SB Inc | 2 | $44 |
| Sanofi | 1 | $30 |
| Arcutis Biotherapeutics, Inc. | 1 | $23 |
| Amgen | 1 | $20 |
| Sun Pharmaceutical Industries Inc. | 1 | $19 |
| Lilly USA, LLC | 1 | $19 |
| Strata Skin Sciences, Inc. | 1 | $16 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 1 | $15 |
| LEO Pharma Inc. | 1 | $11 |
How this compares
$578 in reported general payments places this provider in the 30th percentile of 626 dermatology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Clobetasol Propionate | 121 | $6,950 |
| Ivermectin | 26 | $6,562 |
| Ketoconazole | 374 | $6,141 |
| Betamethasone Dipropionate | 113 | $4,679 |
| Naftifine Hcl | 17 | $3,292 |
| Metronidazole | 50 | $2,762 |
| Tacrolimus | 14 | $2,319 |
| Doxycycline Hyclate | 59 | $2,224 |
| Triamcinolone Acetonide | 157 | $1,739 |
| Halobetasol Propionate | 16 | $1,653 |
| Fluorouracil | 24 | $1,650 |
| Clindamycin Phosphate | 52 | $1,515 |
| ValacyclovirValacyclovir Hcl | 57 | $1,492 |
| Hydrocortisone Valerate | 15 | $1,472 |
| Fluocinonide | 53 | $1,444 |
Paid to pharmacies, not to this prescriber.
Other dermatology in Media
- Victoria WerthPhiladelphia$7.2M
- Laura FerrisPittsburgh$4.3M
- Joel GelfandPhiladelphia$3.6M
- Scott GottliebExton$3.4M
- Lawrence ParishPhiladelphia$2.9M
- Stephen SchleicherSugarloaf$2.3M
- Douglas KressWexford$2M
- Stephen HessPhiladelphia$1.7M
- Joe TungPittsburgh$1.5M
- Joslyn Sciacca-KirbyHershey$1.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.